Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > I am sure THTX seen this

<< Previous

Bullboard Posts

Next >>

Comment by LouisWon Apr 14, 2023 12:28am

108 Views

Post# 35394518

RE:I am sure THTX seen this

One of the slide says Adiposity is associated with cognitive dysfunction. It reminds me that tesamorelin was demonstrated to potetially improve cognition. The relationship between VAT and Alsheimer's disease was also investigated.

https://clinicaltrials.gov/ct2/show/NCT02572323?term=tesamorelin&draw=2&rank=3
https://pubmed.ncbi.nlm.nih.gov/35323701/

The study will be completed in May 2023. Hope TH can announce the result by then if the data is good.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"